Skip to main content

Circio Holding

Circio Holding ASA (formerly Targovax ASA) is a Norwegian clinical-stage biotechnology enterprise specializing in the research, development, and commercialization of next-generation circular RNA (circRNA) gene therapies and cancer immunotherapies, prominently featuring its proprietary circRNA technology platform (circDirect) and targeted tumor-infiltrating therapies. The company conducts advanced preclinical and clinical research evaluating novel genetic constructs designed to improve stability and expression of therapeutic proteins for oncology and genetic diseases. Its core business operations encompass biotechnology R&D, circular RNA platform engineering, clinical trial execution, and collaborative biopharmaceutical licensing. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its research activities through public equity offerings, grants, and strategic research partnerships. Circio Holding holds a pioneering market position in circular RNA gene therapy development. The company is headquartered in Oslo, Norway, and its shares trade on Euronext Oslo Børs.

4 of the funds FundTelligence covers report a position in Circio Holding.

Legal name
Circio Holding ASA
Sector
Health Care
Country
Norway
Funds holding it
4

Funds holding Circio Holding

Loading...